Introduction {#sec1-1}
============

In Ayurveda, *Mutraghata* has been defined as a syndrome of obstructive urinary pathology due to deranged function of *Vata Dosha*, particularly *Apana Vata* (a type of *Vata* responsible for excretory function). Twelve types of *Mutraghata*\[[@ref1]\] are mentioned in *Sushruta Samhita Uttaratantra*. The symptoms such as retention of urine, incomplete voiding, dribbling, hesitancy and incontinence of urine are found in *Mutraghata*; these features probably reflect lower urinary tract symptoms. Based on these features, *Mutraghata* bears a close resemblance with benign prostatic hyperplasia (BPH). BPH is a nonmalignant enlargement of the prostate gland caused by excessive growth of the prostatic tissue and is the most common benign neoplasm of aging men mainly above 40 years.\[[@ref2]\] The overall incidence rate of BPH is 15/1000 men/year. The prevalence of histologically diagnosed prostatic hyperplasia increases from 8% in men aged 31--40 years, to 40--50% in men aged 51--60 years and to \>80% in men elder than 80 years.\[[@ref3]\] The management of BPH is either through a surgical approach (e.g. open prostatectomy, transurethral resection of the prostate, cryotherapy etc.) or by conservative treatment using drugs (e.g. hormonal therapy) in the modern medicine. In case of hormonal therapy, though there are some advantages, the complications such as loss of libido, impotence and gynecomastia are unwanted effects encountered in clinical practice. In a surgical procedure, prostatectomy is choice, but it also has many complications like postoperative morbidity, impotence, retrograde ejaculation etc. The other procedure is Transurethral Resection of the Prostate (TURP), which is also not free from complications and recurrence rate is around 15% in 5--8 years after TURP.\[[@ref4]\] In Ayurveda, *Sushruta* has given regimen consisting of *Kashaya* (decoction), *Kalka* (paste), *Ghrita* (medicated ghee), *Kshara* (alkalizers), etc. to combat this condition.\[[@ref5]\] The formulations having property of pacification of *Vata*, *Vatanulomana*, anti-inflammatory, scraping and diuretic effect and therapeutic procedures such as *Matra Basti* and *Uttara Basti* are recommended to normalize the function of urinary system by reducing the size of the prostate, clearing the bladder outlet obstruction and to enhance the tone of urinary bladder. *Matra Basti* is treatment for vitiated *Vata* where no strict restrictions are required. Hence, this research work was planned to assess the efficacy of *Kanchanara Guggulu*, which has *Vata-Kapha* pacifying, anti-inflammatory, cyst dissolving properties and *Bala Taila* *Matra Basti* in the management of *Mutraghata* (BPH).

Aims and objectives {#sec2-1}
-------------------

The aim of this study was to evaluate the clinical efficacy of *Kanchanara Guggulu* (KG) orally and *Bala Taila Matra* Basti in the management of *Mutraghata* with special reference to BPH.

Materials and Methods {#sec1-2}
=====================

The patients having signs and symptoms of *Mutraghata* (BPH) were selected from the outpatient department and inpatient department of Shalya Tantra. The trial formulations *Bala Taila* and *Kanchanara Guggulu* (KG) were prepared and supplied by Pharmacy, Gujarat Ayurved University, Jamnagar. Before registering the patients in clinical trial, clearance from the Institutional Ethics Committee was obtained, vide letter no. PGT/7-A/Ethics/2013-14/1767 Dated 10/09/2013. The trial has been registered in CTRI with registration No. CTRI/2015/07/006010, date of first enrolment was February 19, 2014 and date of completion of the trial was January 20, 2015.

Inclusion criteria {#sec2-2}
------------------

Age between 40 and 70 yearsPatients having classical signs and symptoms of *Mutraghata* (BPH).

Exclusion criteria {#sec2-3}
------------------

Age below 40 years and above 70 yearsPatients of malignancy, congenital deformities of the urogenital tract or any abdomino-pelvic pathology other than BPHSystemic diseases such as uncontrolled systemic arterial hypertension and diabetes mellitus, tuberculosis, paralysis and parkinsonism known cases of heart disease were excluded from the study

Diagnostic criteria {#sec2-4}
-------------------

Patients having signs as enlarged prostate size and decreased urinary flow rate and symptoms like retention, incomplete voiding, dribbling, hesitancy and incontinence of urine were diagnosed as a case of *Mutraghata* (BPH)International Prostate Symptom Score (IPSS) (based on the guidelines of American Urological Association) was used to evaluate subjective complaints of patients before and after the administration of the therapy, average urine flow rate (AUFR) measurement (manually), ultrasonography (USG) findings of the prostate gland and post voidal residual urine (PVRU) volume and per rectal digital examination for the prostate was also done.

Investigations {#sec2-5}
--------------

In all patients, the following laboratory and radiological investigations were carried out before and after treatmentRoutine hematological examination: Hb%, complete blood count, erythrocyte sedimentation rateBiochemical examination of fasting blood sugar, postprandial blood sugar, serum creatinine, serum alkaline phosphatase and blood ureaRoutine and microscopic examination of urine and stoolUSG abdomen and prostateX-ray kidney, ureter, and bladder.

Trial drugs {#sec2-6}
-----------

*Bala Taila* (BT): The contents of *Bala Taila* are *Atibala (Abutilon indicum* (L.) Sweet)\[[@ref6]\] and *Tila Taila* (*Sesamum indicum* L.)\[[@ref7]\] which were prepared as per the *Snehapaka Kalpana* (clssical procedure to prepare medicated oil) and procured from Pharmacy Gujarat Ayurved University, Jamnagar*Kanchanara Guggulu* (KG): It was prepared as per the reference given in *Sharangdhara Samhita*.\[[@ref8]\]

Clinical study design {#sec2-7}
---------------------

Registered patients by coin-toss method were divided into two groups, group A (*Bala Taila Matra Basti*) and group B (*Bala Taila Matra Basti* and *Kanchanara Guggulu*). All the patients were followed up till 1 month.

Group A: *Bala Taila Matra Basti* 60 ml once a day, administered to selected 12 patients before breakfast for 21 daysGroup B: *Bala Taila Matra Basti* 60 ml was given once a day, administered to selected 18 patients, before breakfast for 21 days along with *Kanchanara Guggulu* orally 1g (2 tab., 500mg each) three times a day after food with lukewarm water for 21 days.

Assessment criteria {#sec2-8}
-------------------

Subjective criteria

Improvement in the symptoms as per the IPSS.\[[@ref9]\]

Objective criteria {#sec2-9}
------------------

Changes in residual urine volume. \[[Table 1](#T1){ref-type="table"}\]Changes in urine flow rate. \[[Table 2](#T2){ref-type="table"}\]Changes in prostatic size as assessed by per rectal digital examination and USG study. \[[Table 3](#T3){ref-type="table"}\]

###### 

Gradation of residual urine volume

  Post viodal residual urine volume (PVRU)   Gradation
  ------------------------------------------ -----------
  Nil (up to 30 cc)                          0
  30--60 cc                                  1
  60--90 cc                                  2
  90--120 cc                                 3
  \>120 cc                                   4

###### 

Gradation of urine flow rate

  Urine flow rate (UFR)       Gradation
  --------------------------- -----------
  Normal or more (≥15 ml/s)   0
  11--15 ml/s                 1
  7--11 ml/s                  2
  3--7 ml/s                   3
  0--3 ml/s                   4

###### 

Gradation of prostate size (volume)

  Prostate size as per USG (volume)   Gradation
  ----------------------------------- -----------
  Up to normal (14--26 cc)            0
  26--36 cc                           1
  36--46 cc                           2
  46--56 cc                           3
  \>56 cc                             4

Overall assessment criteria {#sec2-10}
---------------------------

Complete remission: 100% relief in subjective, objective findings and IPSS parametersMaximum improvement: 76%--99% relief in subjective, objective findings and IPSS parametersModerate improvement: 51%--75% relief in subjective, objective findings and IPSS parametersMild improvement: 26%--50% relief in subjective, objective findings and IPSS parametersUnchanged: Up to 25% relief in subjective, objective findings and IPSS parameter.

General observations {#sec2-11}
--------------------

All patients were vegetarian and consuming *Madhura Rasa* (sweet taste) and *Snigdha Guna* (oily) food articles, 46.87% of patients were having irregular bowel habit and 37.5% patients had habit of passing hard stool. Maximum 59.37% patients had chronicity of disease up to 1 year \[[Table 4](#T4){ref-type="table"}\].In the present study, nocturia and increased frequency of micturition was found in 87.50% patients. Similarly, other symptoms such as weak stream, dribbling, incomplete voiding, burning micturition and urgency was observed in 81.25%, 75%, 68.75%, 65.63% and 62.50% of the patients respectively. None of the patients suffered from hematuria or dysuria \[[Table 5](#T5){ref-type="table"}\].As per per-rectal examination, maximum patients (53.13%) were noted having prostate enlargement of both lobes, oval shaped (84.37%) with smooth surface (100%). The upper border of the prostate was not approachable in 53.13% patients, median groove of the prostate was palpable in 87.50% and free rectal mucosa and firm consistency of prostate were noted in 100% cases. The size of the prostate gland was mildly enlarged in 59.37% of patients \[[Table 6](#T6){ref-type="table"}\].

###### 

General observations (*n*=32)

  Observation                                        No. of Patients (%)
  ----------------------------- -------------------- ---------------------
  Age group                     61-70                50%
  Religion                      Hindu                96.87%
  Socio -economic status        Lower Middle Class   75.00%
  Nature of work                Physical Labor       53.13%
  Marital status                Married              100%
  Education (primary level)                          84.37%
  Dietetic habit                *Samashana*          81.25%
  *Koshtha* (bowel habit)       *Madhyama*           84.37%
  *Agni* (digestion state)      *Manda*              71.87%
  Dominancy of *Rasa* in diet   *Madhura Rasa*       100%
  *Sigdha Guna*                 93.75                
  *Vaya* (age)                  *Madhyama*           53.13%

###### 

Symptoms wise distribution as per IPSS

  Symptoms              Group A   Group B   Total                 
  --------------------- --------- --------- ------- -------- ---- -------
  Nocturia              10        83.33     18      100.00   28   87.50
  Increased frequency   10        83.33     18      100.00   28   87.50
  Dribbling             11        91.67     13      72.22    24   75.00
  Heamaturia            0         00.00     0       00.00    0    00.00
  Burning micturation   7         58.33     14      77.78    21   65.63
  Dysuria               4         33.33     4       22.22    8    25.00
  Incomplete voiding    6         50.00     16      88.89    22   68.75
  Weak stream           11        91.67     15      88.33    26   81.25
  Urgency               7         58.33     13      72.22    20   62.50

\*IPSS: International Prostate Symptom Score

###### 

Per rectal digital examination findings (*n*=32)

  P/R Digital Findings                Group A   Group B   Total                 
  ----------------------- ----------- --------- --------- ------- -------- ---- --------
  Enlargement of lobes    Bilateral   6         50.00     11      55.00    17   53.13
  Shape                   Oval        10        83.33     17      85.00    27   84.37
  Surface                 Smooth      12        100.00    20      100.00   32   100.00
  Upper border of gland   Unreached   5         41.67     12      60.00    17   53.13
  Median groove           Palpable    10        83.33     18      90.00    28   87.50
  Mobility                Fixed       12        100.00    20      100.00   32   100.00
  Rectal mucosa           Fixed       0         00.00     0       00.00    0    00.00
  Consistency             Firm        12        100.00    20      100.00   32   100.00
  Tenderness              Absent      12        100.00    20      100.00   32   100.00
  Enlargement of gland    Mild        8         66.67     11      55.00    19   59.37

Results {#sec1-3}
=======

Laboratory investigations {#sec2-12}
-------------------------

In both of the groups in significant changes ere found in most of haematological and biochemical parameters.\[[@ref10]\] \[[Table 7](#T7){ref-type="table"}\]

###### 

Effect of therapy on investigations in Group B: (*n*=18)

  Parameters                        Mean Score   %Relief   SD      SE        *T*      *P*      
  --------------------------------- ------------ --------- ------- --------- -------- -------- -------
  Hemoglobin (%)                    13.42        13.67     1.90    0.371     0.087    -2.92    0.010
  Total WBC ( /cumm)                6916.66      7183.33   3.86    1038.09   244.68   -1.09    0.291
  ESR (mm/hr)                       25.78        19.33     25.00   13.06     3.08     2.09     0.052
  FBS (mg/dl)                       103.94       103.0     -0.91   13.36     3.15     0.3      0.768
  PPBS (mg/dl)                      139.1        132.6     4.63    18.63     4.39     1.47     0.160
  Sr. Alkaline Phosphatase (IU/L)   52.05        46.83     10      12.55     2.96     1.765    0.096
  Blood Urea (mg/dl)                30.44        27.22     10.58   7.24      1.71     1.89     0.086
  Sr. Creatinine (mg/dl)            1.15         1.16      -0.97   0.178     0.042    -0.265   0.794
  Urine Albumin (gm/dl)             1.43         1.43      0.0     0.816     0.309    0.0      1.00
  Urine Sugar (mmol/L)              1.25         1.50      -20.0   0.957     0.479    -0.52    0.638
  Urine Pus Cells ( /HPF)           9.36         9.86      -5.34   13.35     3.57     -0.14    0.891

\*\* BT- before treatment, AT- after treatment, SD- standard deviation, SE- standard error

Result on International Prostate Symptom Score {#sec2-13}
----------------------------------------------

Statistically highly significant relief (*P* \< 0.001) was recorded in chief complaints like nocturia, increased frequency of micturition, incomplete voiding, dribbling and weak stream, while significant relief (*P* \< 0.01) was noted in burning micturition and urgency in group A \[[Table 8](#T8){ref-type="table"}\]. Statistically highly significant (*P* \< 0.001) result was noted on almost all symptoms in patients of group B \[[Table 9](#T9){ref-type="table"}\].

###### 

Effect of therapy on IPSS in Group-A (*n*=12)

  International Prostate Symptoms Score (IPSS)   Mean Score   *n*   %Relief   SD(±)   SE(±)   *t*     *P*     
  ---------------------------------------------- ------------ ----- --------- ------- ------- ------- ------- ---------
  Incomplete emptying                            1.4          0.2   12        84.24   0.866   0.25    5.0     \<0.001
  Frequency                                      2.5          0.5   12        77.42   0.603   0.174   11.48   \<0.001
  Intermittency                                  1.2          0.2   7         77.78   0.577   0.218   4.58    0.004
  Urgency                                        2.1          0.2   9         89.47   1.054   0.351   5.376   \<0.001
  Weak stream                                    1.8          0.3   11        80.00   0.522   0.157   9.24    \<0.001
  Straining                                      1.6          0.2   8         84.62   0.744   0.263   5.23    0.001
  Nocturia                                       2.0          0.6   11        69.57   0.934   0.282   5.164   \<0.001
  Quality of life                                3.2          1.4   12        58.33   0.577   0.167   11.00   \<0.001

\*\* BT- before treatment, AT- after treatment, SD- standard deviation, SE- standard error

###### 

Effect of therapy on IPSS in Group-B (*n*=18)

  International Prostate Symptoms Score (IPSS)   Mean Score   *n*    %Relief   SD(±)   SE(±)   *t*     *P*     
  ---------------------------------------------- ------------ ------ --------- ------- ------- ------- ------- ---------
  Incomplete emptying                            2.71         0.76   17        71.74   0.966   0.234   8.282   \<0.001
  Frequency                                      3.11         0.79   18        75.00   0.97    0.23    10.20   \<0.001
  Intermittency                                  1.85         0.34   13        79.17   0.967   0.268   5.447   \<0.001
  Urgency                                        2.21         0.43   14        80.65   0.80    0.21    8.33    \<0.001
  Weak stream                                    2.5          0.43   14        82.86   1.33    0.35    5.84    \<0.001
  Straining                                      1.54         0.23   13        85.00   1.032   0.286   4.57    \<0.001
  Nocturia                                       3.0          0.61   18        79.63   0.916   0.216   11.06   \<0.001
  Quality of life                                3.39         1.56   18        54.10   0.618   0.146   1258    \<0.001

\*\* BT- before treatment, AT- after treatment, SD- standard deviation, SE- standard error

Result on objective parameters {#sec2-14}
------------------------------

Statistically highly significant (*P* \< 0.001) increase was noted in AUFR and significant (*P* \< 0.01) reduction was recorded in prostate size as well as PVRU in group A \[[Table 10](#T10){ref-type="table"}\]. Statistically highly significant (*P* \< 0.001) effect in reducing PVRU and increasing AUFR and significant (*P* \< 0.05) decrease in the size of enlarged prostate gland was noted in patients of group B \[[Table 11](#T11){ref-type="table"}\].

###### 

Effect of therapy on objective parameters in Group-A: (*n*=12)

  Objective parameters                Mean Score   %Relief   SD(±)   SE(±)   *t*     *P*     
  ----------------------------------- ------------ --------- ------- ------- ------- ------- ---------
  Prostate size & volume              1.75         1.17      33.34   0.515   0.149   3.924   0.002
  Post-voidal residual urine volume   1.8          0.45      88.89   0.894   0.4     4.0     0.016
  Average urine flow rate             1.2          0.3       75.00   0.568   0.18    5.014   \<0.001

\*\* BT- before treatment, AT- after treatment, SD- standard deviation, SE- standard error

###### 

Effect of therapy on objective parameters in Group-B (*n*=18)

  Objective parameters                  Mean Score   %Relief   SD(±)   SE(±)   *t*     *P*     
  ------------------------------------- ------------ --------- ------- ------- ------- ------- ---------
  Prostate size & volume                2.8          2.35      16.67   0.717   0.174   2.704   0.016
  Post - voidal residual urine volume   1.11         0.11      90.00   0.5     0.167   6.0     \<0.001
  Average urine flow rate               1.69         0.41      74.07   0.577   0.144   8.66    \<0.001

\*\* BT- before treatment, AT- after treatment, SD- standard deviation, SE- standard error

Overall result of therapy (group wise) {#sec2-15}
--------------------------------------

In group A, maximum improvement was seen in 3 patients (25.00%), moderate improvement was seen in 8 patients (66.67%), and mild improvement was observed in 1 patient (8.34%) \[[Table 12](#T12){ref-type="table"}\]. Similarly, in group B, maximum improvement was found in 10 patients (55.56%), moderate improvement in 7 patients (38.89%) and mild improvement in 1 patient (5.56%) only. None of the patients had complete remission or remained unchanged in either of the groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Overall Effect of therapy in Group A: (*n*=12)

  Overall effect of therapy   Effect on IPSS   Effect on objective parameter   Overall effect of therapy               
  --------------------------- ---------------- ------------------------------- --------------------------- ------- --- -------
  Complete remission          0                00.00                           0                           00.00   0   00.00
  Maximum improvement         10               83.34                           2                           16.67   3   25.00
  Moderate improvement        1                8.34                            3                           25.00   8   66.67
  Mild improvement            1                8.34                            7                           58.34   1   8.34
  Unchanged                   0                00.00                           0                           00.00   0   00.00

###### 

Overall effect of therapy in Group B (*n*=18)

  Overall effect of therapy   Effect on IPSS   Effect on objective parameter   Overall effect of therapy                
  --------------------------- ---------------- ------------------------------- --------------------------- ------- ---- -------
  Complete remission          1                5.56                            0                           00.00   0    00.00
  Maximum improvement         13               72.23                           2                           11.12   10   55.56
  Moderate improvement        2                11.12                           8                           44.45   7    38.89
  Mild improvement            2                11.12                           5                           27.78   1    5.56
  Unchanged                   0                00.00                           3                           16.67   0    00.00

Overall effect of therapy {#sec2-16}
-------------------------

Maximum improvement i.e. 76.67 % was found in the symptoms like retention of urine, incomplete voiding, dribbling, hesitancy and incontinence of urine. While mild improvement (40.00%) was observed in average urine flow rate (AUFR), post voidal residual urine (PVRU) volume and size of the prostate. \[[Table 14](#T14){ref-type="table"}\]

###### 

Overall effect of therapy on different parameters (*n*=30)

  Overall effect of therapy   Effect on IPSS   Effect on objective parameter        
  --------------------------- ---------------- ------------------------------- ---- -------
  Complete remission          1                3.34                            0    0
  Maximum Improvement         23               76.67                           4    13.33
  Moderate Improvement        3                10.00                           11   36.67
  Mild Improvement            3                10.00                           12   40.00
  Unchanged                   0                00.00                           3    10.00

Discussion {#sec1-4}
==========

In Ayurveda, *Mutraghata* is a broad term as it covers most of the pathological entities of the urinary system. Total, 12 types of *Mutraghata* are mentioned by *Acharya Sushruta*\[[@ref11]\] and 13 types by *Acharya Charaka. Mutraghata* comprises of two different words, that is, "*Mutra*" means urine and "*Aghata*" means obstructive pathology. The features of *Mutraghata* such as retention of urine (*Mutrasanga*) and pain in suprapubic region are observed due to obstructive pathology and can be correlated with BPH on the basis of its symptoms and signs. In old age, there is deranged function of *Vata Dosha*, particularly *Apana Vata* which is the prime causative factor and it also disturbs with *Kapha Dosha*. Consequently, vitiated *Vata* and *Kapha Dosha* affect to *Mutravaha Srotasa* and derangments occurs in *Basti* (urinary system) and results in *Mutraghata*. Hence, the drugs having *Vata-Kapha* pacifying property, *Srotoshodhana* (cleaning the channels), *Lekhana* (scraping), *Shophahara* (anti-inflammatory), *Mutrala* (diuretic) and along with digestive properties are helpful to break the *Samprapti* of *Mutraghata* (BPH).

*Kanchanara Guggulu* is an Ayurvedic formulation having properties of *Vata-Kapha Dosha* pacification, *Lekhana* and *Shothahara* (anti-inflammatory).\[[@ref12]\] Because of these properties, *Kanchanara Guggulu* may check the changes of prostatic tissues and regulates the urinary function.\[[@ref13]\] *Matra Basti* is the procedure to control *Vata Dosha*, especially *Apana Vata*.\[[@ref14]\] All *Acharya* have recommended *Matra Basti* as a line of management of *Mutraghata* to improve urinary function and to remove the obstruction.

Most of the patients in this study (50%) were from the age group of 61--70 years. This age group favors the vitiation of *Vata Dosha* and might be a cause for the development of *Mutraghata*, especially hyperplasia of the prostate gland. Modern science has also reported that benign changes in the prostate gland are more prevalent in sixth and seventh decades of life. Most of the patients had chronicity up to 1 year. In the initial stage, the symptoms of BPH are not severe; hence, the patients ignore the complaints till the condition becomes chronic. *Samashana* (mixing of wholesome food with unwholesome food) was found in the majority of the patients. *Ama* (undigested food) is the causative factor for the manifestation of *Mutraghata* as described by *Charaka* and more formation of Ama is seen in the person habitual of *Samashana*. Disturbed sleep was found in maximum number of patients, which might be due to increased frequency of micturition at night. Constipation was found in 37.5% of the patients, which might be due to faulty dietary habits such as *Samashana* and deranged *Apana Vayu*.

In group A, *Bala Taila Matra Basti* provided 84.24% relief in incomplete voiding of urine, 77.42% relief in increased frequency, 77.78% relief in intermittency, 89.47% relief in urgency, 80% relief in weak stream, 84.62% in straining and 69.57% in nocturia. The quality of life was improved in 58.33% of patients. These results were highly significant (*P* \< 0.001) in all of the above mentioned symptoms except intermittency, which was statistically significant (*P* \< 0.01), whereas in objective findings, the size of the prostate was reduced up to 33.34%. Reduction of 88.89% was found in PVRU and AUFR was improved up to 75%. This encouraging result was found because *Matra Basti* has the potency to pacify vitiated *Apana Vata*, which is the prime factor for the manifestation of *Mutraghata*. The properties of *Bala Taila* such as muscle tone building, rejuvination and anti-inflammatory activities help to improve the function of the detrusor muscle. *Atibala* is an important ingredient of *Bala Taila* which contains saponin as a chemical component. It has diuretic and anti-inflammatory actions.\[[@ref15]\] Hence, it is obvious that *Bala Taila* might have contributed in improvement of bladder function by increasing the bladder tone as well as reducing the size of the prostate. Ultimately the bladder outflow obstruction was improved and overall quality of life was improved with *Matra Basti*.

In group B, *Kanchanara Guggulu* and *Bala Taila Matra Basti* provided 71.74% rellief in incomplete voiding, 75% in increased frequency, 79.17% in intermittency, 80.65% in urgency, 82.86% in weak stream, 85.00% in straining and 79.63% in nocturia. The quality of life was improved up to 54.10%. These obtained results were statistically highly significant (*P* \< 0.001), whereas in objective findings, the size of the prostate was reduced up to 16.67%, PVRU was improved up to 90.00% and 74.07% increase was observed in AUFR.

The drug *Kanchanara Guggulu* having the properties of *Vata-Kapha Shamana, Pachana, Basti Shodhana* and *Mootrala* etc., might have helped to enhance the function of the bladder. The drug *Varuna* (*Crateva nurvala* Buch.-Ham.) is one of the ingredients of this formulation containing Kampferol and quercetin flavonoids. These chemical constituents act as inhibitor of estrogenic receptor.\[[@ref13]\] Hence, *Kanchanara Guggulu* was helpful in reducing the size of the prostate. Ingredients of *Kanchanara Guggulu* like, *Triphala* and *Trikatu* contains ascorbic acid which helps to relax the smooth muscle of the prostate and bladder neck to relieve pressure and improve urine flow rate.\[[@ref16]\]

On comparison to the effect of therapy as per the IPSS pattern, group A has shown better result as compared to group B (79.15%). There was no statistically significant difference (*P* = 0.296) within two groups in the subjective parameters. It is suggested that changes that occurred with the treatment were not enough to exclude the possibility that the difference was due to chance. Hence, both groups had given parallel effect on symptoms/IPSS score of disease as per the statistical analysis.

According to all objective parameters such as prostate size, PVRU volume and average UFR, group A had shown better effect, that is, 65.74% relief as compared to group B (60.25%). But in both groups A- UFR was found increased statistically highly significant, whereas insignificant reduction (*P* \> 0.05) were observed in prostate size and PVRU as per statistics.

Overall effect of therapy {#sec2-17}
-------------------------

During the entire period of therapy, there was no any untoward effect or adverse drug reaction observed in any of the patients of the group.

Conclusion {#sec1-5}
==========

This study concluded that 60 ml *Bala Taila Matra Basti* is effective and tolerable in the patients of *Mutraghata* (Benign Prostatic Hyperplasia). As the Benign Prostatic Hyperplasia is progressive degenerative disorder long term treatment may be needed to provide maximum relief in such patients.
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